This platform offers standard in vitro experimentation procedures for the functional validation of candidate genes and biomarkers, and for the efficacy and toxicological evaluation of new drugs, biomaterials and biomarkers.
At the moment, the platform offers standardin vivo experimentation procedures for the evaluation of new therapeutic targets, nanotherapies and biomarkers in the field of oncology and rare diseases.
Dr. Simó Schwartz Jr. assumes the general direction of the Blood and Tissue Bank after 16 years at VHIR
Dr. Simó Schwartz Jr. has been appointed as the new general director of the Blood and Tissue Bank, replacing Dr. Enric Argelagués, who leaves his position today...Read more
Vall d’Hebron leads a clinical study testing the use of nanoparticles for the treatment of locally advanced pancreatic cancer
Nanomedicine has emerged as a potential therapy for pancreatic cancer, a disease with a 5-year survival rate as low as 5%. The international project NoCanTher was...Read more
Nanomedicine & Bioengineering
Rafael D, Merce Roca Melendres, Andrade F, Montero S, Martinez-Trucharte F, Vilar-Hernandez M, Francisco Duran-Lara, Schwartz S Jr, Abasolo I Int J Pharm. 2021 Jul...Read more